Agencies
Services
Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 20, 2013
| Drug Name | Review Type | Class | Manufacturer |
|---|---|---|---|
| Quillivant XR | New Drug Initial Review | Stimulants/ADHD | Pfizer |
| Xeljanz | New Drug Initial Review | Rheumatoid Arthritis | Pfizer |
| Aubagio | New Drug Initial Review | Multiple Sclerosis | Genzyme |
| Eliquis | New Drug Initial Review | Oral Anticoagulant | Bristol Myers-Squibb |
| Sklice | New Drug Initial Review | Pediculicide | Sanofi Pasteur |
| Gattex | New Drug Initial Review | GLP-2 | NPS Pharmaceuticals |
| Oxtellar XR | New Drug Initial Review | Anticonvulsant | Supernus Pharmaceuticals |
| Tudorza Pressair | New Drug Initial Review | Long-acting Anticholingeric | Forest |
| Natroba | New Drug Appeal | Pediculicide | ParaPRO |
| Brilinta | PDL Appeal | Platelet Aggregation Inhibitor | AstraZeneca |
| Latuda | PDL Appeal | Atypical Antipsychotic | Sunovion |